CAR T-Cell Therapy as a Second-Line Treatment for LBCL

News
Video

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Recent Videos
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Chris Wright, MD, PhD, on Annelloviruses, a Potential Alternative to AAV for Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – November 22, 2024

CGTLive Staff
November 22nd 2024
Article

Review top news and interview highlights from the week ending November 22, 2024.

Molly Borchardt, PharmD

Improving Patient Access to Cell Therapy Through Decentralized Manufacturing

Molly Borchardt, PharmD;Phil Cyr, MPH;Erin Lopata, PharmD, MPH;Jason Foster, MBA
November 21st 2024
Article

Decentralized manufacturing could transform cell therapy delivery by reducing delays, costs, and logistical hurdles to improve patient outcomes.

Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 20, 2024

Noah Stansfield
November 20th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – November 15, 2024

CGTLive Staff
November 15th 2024
Article

Review top news and interview highlights from the week ending November 15, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – November 13, 2024

Around the Helix: Cell and Gene Therapy Company Updates – November 13, 2024

Noah Stansfield
November 13th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101

Noah Stansfield
November 10th 2024
Article

The patient died of respiratory failure 4 months after receiving BEAM-101.

© 2024 MJH Life Sciences

All rights reserved.